CA1135260A - Maytansinoids, their production and use - Google Patents

Maytansinoids, their production and use

Info

Publication number
CA1135260A
CA1135260A CA000353518A CA353518A CA1135260A CA 1135260 A CA1135260 A CA 1135260A CA 000353518 A CA000353518 A CA 000353518A CA 353518 A CA353518 A CA 353518A CA 1135260 A CA1135260 A CA 1135260A
Authority
CA
Canada
Prior art keywords
maytansinol
alpha
process according
4alkyl
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000353518A
Other languages
French (fr)
Inventor
Hiroshi Akimoto
Osamu Miyashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of CA1135260A publication Critical patent/CA1135260A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Abstract of the Disclosure Novel maytansinoids of the formula:

Description

i^'''`` ~l~S~

MAYTA~ISrNOIDS, THEIR P~ODDC~I N AND USE
This invention relates to novel maytansinoid ccmpGunds of the formula: y OCOR

~ ~ N (I) lo : -wherein Y is H or Cl, and R is C2_15alkyl, phenyl-Cl_4alkyl, pyridyl-Cl 4aIkyl, imidazolyl-Cl 4alkyl, indolyl-Cl 4aIkyl, furyl-Cl 4alkyl or thienyl-Cl 4alkyl, any of said groups being sub-stituted bv hydroxyl, protected hydroxyl, halogen or Cl 5alkanoyloxy at its ~-carkon atcm or its ~-carbon atcm or koth its ~- and ~-carkon atoms, and to a method for production and use of the ccm-pounds (I).
Ref~rring to the above form~la (I), the C2 15alkyl group may for example be ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decvl, undecyl, dodecyl, tridecyl, tetrad~.cyl, pentadecyl, neopentyl or
2-ethylhexyl. A preferred aIkyl group is C2 10alkyl.
As examples of Cl 4alkyl moieties in the phenyl-Cl 4alkyl and heterwycle-Cl 4aIkyl groups, there may be mentioned methyl, ethyl, propyl, isopropyl, butyl, isobutyl and sec-butyl, preferably methyl and ethyl. Accordingly, - 1 - ~g . , the phenyl-Cl 4alkyl group may for example be benzyl, phenethyl, 1-phenylethyl (~-methylbenzyl), 1- or 2-methyl-2-phenylethylO The pyridyl-Cl 4alkyl group includes 2-,
3- or 4-pyridylmethyl and 2-(2-, 3- or 4-pyridyl)ethyl~
The imidazolyl-Cl 4alkyl group includes imidazolylmethyl and imidazolylethylO The indolyl-Cl 4alkyl group includes indolylmethyl and indolylethyl The furyl-Cl 4alkyl group includes 2 or 3-furfuryl and 2-(2- or ~-furyl)ethylO
~he thienyl-Cl 4alkyl group includes 2- or 3-thenyl and 2-(2- or 3-thienyl)ethyl~
~ he above-mentioned C2 15alkyl, phenyl-Cl_4alkyl and heterocycle-Cl 4alkyl groups have hydroxyl, halogen or Cl 5alkanoylox~ as a substituent or substituents at the ~- and~or ~-positionO Said halogen atom includes chlorine, bromine, iodine and fluorine, and said Cl 5alkanoyloxy group includes formyloxy, acetyloxy, propionyloxy, butyryl-oxy, isobutyryloxy, pentanoyloxy and isopentanoyloxyO
When both of the a- and ~positions are substituted by hydroxyls, said hydroxyls may be protected in the form of acetalO In this specification, the a-position means the adjacent carbon atom in R-groups to the carbonyl group connecting with the hydroxyl group at the 3-position of maytansinol, and the ~-position means the next one to the a-position~
~ he groups designated by R may optionally have suitable substituents at substitutable positions, in addition to the above-mentioned substituent, iOeu hydroxyl, halogen or Cl 5alkanoyloxy at ~- and/or ~-positionO Said substituents include Cl 4alkoxy (eOg methoxy, ethoxy, propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy), Cl 4alkanoyloxy (eOgO formyloxy, acetyloxy, propionyloxy, n-butyryloxy, isobutyryloxy), C2 L~alkoxycarbonyl (eOgO
methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, iso-propoxycarbonyl), halogen (eOgO chlorine, fluorine, bromine, iodine), nitro, cyano, trifluoromethyl, di-Cl 4alkylamino (eOgO dimethylamino, diethylamino, dipropylamino, diiso-propylamino, dibutylamino), Cl 4alkylthio (eOg~ methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert butylthio), Cl 4alkyl-sulfinyl (eOgO methylsulfinyl), Cl 4alkylsulfonyl (eOgO
methylsulfonyl), Cl 4alkanoylamino (eOgO formylamino, acetylaminot propionyla~ino, butyrylamino, isobutyrylamino), sulfamoyl and so onO When R is phenyl-Cl 4alkyl or heterocycle-Cl 4alkyl, in addi-tion to the substituents mentioned ~ust above, there may be mentioned, as substi-tue~nts, Cl 4alkyl (eOgO methyl, ethyl~ n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl) and C2 4alkanoyl (eOgO acetyl, propionyl, n-butyryl, isobutyryl)O These substituents may be the same or different and may tot~l 1 to 3u When hydroxyl, halogen or Cl 5alkanoyloxy at the ~-or ~-position is designated as X and the adjacent carbon ~L3SZ~3 atom to the carbonyl group connecting with the hydroxyl group at the 3-position of maytansinol is defined as the first (1- or ~-) position, examples of the groups R may be mentioned as followsO
~ he relevant ~roups to C2 15alkyl may for example be l-X-ethyl, l-X-propyl~ l-X-butyl, l-X-isobutyl, l-X-pentyl, l-X-isopentyl, l-X-hexyl, l-X-octyl, l-X-nonyl, l-X-decyl, l-X-undecyl, l-X-dodecyl, l-X-tridecyl, l-X-pentadecyl, l-X-l-methylethyl, l-X-l-methylpropyl, l-X-l-methylbutyl, l-X-l-methylisopentyl, 2-X-ethyl, 2-X-propyl, 2-X-butyl, 2-X-l-methylbutyl, 2-X-isopropyl, 2-X-l-ethylethyl, 2-X-pentyl, 2-X-nonyl, 1,2-di-X-ethyl, 1,2-di-X-l-methylethyl and 1,2-di-X-propylO As examples of further substituted groups, there may be mentioned l-X-3-methylthiopropyl, l-X-3-ethylthiopropyl, 1-X-3-methylsulfinylpropyl, 1-X-3-methylsulfonylpropyl, l-X-2-methoxyethyl, 1-X-3-ethoxy-carbonylpropyl, l-X-2-ethoxycarbonylethyl and 2-X-3-ethoxycarbonylpropyl O
~ he relevant groups to phenyl-Cl 4alkyl may for example be a-X-benzyl, l-X-2-phenylethyl, a~ -methylbenzyl, l-X-l-methyl-2-phenylethyl and 2-X-l-phenylethylO As e~amples of further substituted groups, there may be mentioned groups formed by replacing the phenyl in the above groups ~ith a substi-tuted phenyl such as 2- t 3- or
4-methylphenyl, 4-ethylphenyl, 2-, 3- or 4-chlorophenyl, : 3- or 4-bromophenyl, 3- or 4-fluorophenyl, 2,4- or 3,4-" ~

dichlorophenyl, 2-, 3- or 4-methoxyphenyl, 2,5- or ~,4-dimethoxyphenyl, 4-hydroxyphenyl, 4-acetoxyphenyl, 4-butoxyphenyl, 4-iodophenyl, 3- or 4-trifluoromethylphenyl, 2- or 4-nitrophenyl, 4-cyanophenyl, 4-methanesulfonylamino-phenyl, 2-chloro-4-methoxyphenyl, 2-chloro-5-methylphenyl, 2,4,6-trimethylphenyl or 3,4,5-trimethoxyphenylO
~ he rele~ant groups to indolyl-Cl 4alkyl may for example be l-X-l-(3-indolyl)methyl and 1-X-2-(3-indolyl) ethyl, and further substituted groups may for example be l-X-2-(5-chloro-3-indolyl)ethyl and 1-X-2-(5-hydroxy-3-indolyl)ethyl~
~ he relevant groups to imidazolyl-Cl 4alkyl may for example be l-X-2-(4(5)-imidazolyl)ethyl and 1-X-2 methyl-4-imida7.olyl)ethyl a ~ he relevant groups to furyl-Cl 4~1~y1 may for example be l-X-1-(2-furyl)methyl, 1-X-1-(3-furyl)methyl~ 1-X-2-(2-furyl)ethyl and l-X-2-(3-furyl)ethyl, and further substi-tuted groups may for example be l-X-1-(5-methyl-2-furyl)-methyl, l-X-1-(5-methoxycarbonyl-2-furyl)methyl, l-X-l-(5-nitro-2~furyl)methyl and 1-X-2-(5-ethoxycarbonyl-2-furyl)ethyl a The relevant groups to thienyl-Cl 4alk~1 ~ay for example be l-X-1-(2-thienyl)methyl, 1-X-1-(2-thienyl)ethyl, l-X-l-(3-thienyl)methyl~ 1-X-2-~2-thienyl)ethyl and 1-X-2-(3-thienyl)ethyl, and further substituted groups may for example be 3- or 5-methyl-1-X-1-(2-thienyl)ethyl and 1-X-1-(3,5-dimethyl-2-thienyl)methylO

The relevant groups to pyridyl-Cl 4alkyl may for example be l-X-1-(2-, 3- or 4-pyridyl)methyl, 1-X-2-(2-, 3- or 4-pyridyl)ethyl and 1,2-di-X-2-(3-pyridyl)ethyl, and further substituted groups may for example be l-X-2-(6-methyl-2-pyridyl)ethyl and 1-X-2-(2,6-dichloro-~-pyridyl)ethylO
The maytansinoid compound (I) of the present invention can be produced by acylating maytansinol or dechloro-maytansinol of the formula:

Co~3 (II) N ~ O

CH~ CH30 wherein Y is as defined above, with a carboxylic acid of the formula:
RCOOH (III) wherein R is as defined above, or its reactive derivative with respect to the carboxyl function thereofO
An exemplary reaction procedure comprises acylatin~
a compound (II) with a carboxylic acid (III) in the presence of a carbodiimide~ Based on compound (II), carboxylic acid (II~) may be used in an amount of, for example, about 1 to 50 molar equivalents a~d, in many cases, is preferably employed in an amount of about 1 - 20 molar equivalents.
The carbodiimide may be used in an amount of about 1 to 70 molar equivalen-ts based on compound (II) and, in many cases7 is preferably employed in an amount of abou-t 1 - 30 molar equivalentsO
~ he usable carbodiimide is preferably dicyclohexyl-carbodiimide, although such other carbodiimides may also be employed as, for example, diphenylcarbodiimide, di-o-tolylcarbodiimide, di-p-tolylcarbodiimide, di-tert-butyl-carbodii~ide, l-cyclohexyl-3-(2-morpholinoethyl)carbodiimide, l-cyclohexyl-~-(4-diethylaminocyclohexyl)carbodiimide, l-ethyl-3-(2-diethylaminopropyl)carbodiimide and 1-ethyl-3-(3-dimeth.ylaminopropyl)carbodiimideO
~ his acylation reaction may be carried out in a suitable solventO Examples of such solvent include esters (eOgO ethyl acetate), ethers (eOgO diethyl ether, dioxane, tetrahydrofuran), halogenated hydrocarbons (e gO methylene chloride, chloroform), nitriles (eOgO acetonitrile~, aromatic hydrocarbons (eOgO benzene), nitromethane, pyridine, dimethylformamide, dimethylsulfoxide, sulfolane, etcO, as well as appropria-te mixtures of such solventsO
~ his reaction may be usually carried out at a suitable temperature from ice-cooling to the re~lux point of the reaction systemO

This acylation reaction can be advantageously hastened wi~h the aid of a catalyst capable of promoting acylation of compoun~ (II). The catalyst may be an appropriate acid or baseO The basic catalyst includes, among others, tertiary amine compounds (e~gO aliphatic tertiary amines such as triethylamine; aromatic tertiary amines such as pyridine, ~ , or ~-picoline, 2,6-lu-tidine, 4-dimethyl-aminopyridine, 4-(1-pyrrolidinyl)pyridine, dimethylaniline, diethylaniline), halogenated a].kali metals (eOgO potassium fluoride, anhydrous lithium iodide), salts of organic acids (eOgO sodium acetate) and so forthO The acid catalyst includes, among others, Lewis acids [eOgO anhydrous zinc chloride, anhydrous aluminum chloride (AlC13), anhydrous ferric chloride, titanium tetrachloride (TiC14), stannic tetrachloride (SnC14), antimony pentachloride, cobalt chloride, cupric chloride, boron tri.fluoride etherate, etcO], in.organic strong acids (eOgO sulfuric acid, per-chloric acid, hydrochloric acid, hydrobromic acid, etcO), organic strong acids (eOgO benzenesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, trichloroacetic acid, etcO), acidic ion exchange resins (e D gO polystyrene-sulfonic acid), etcO The catalyst is used in a catalytic amount sufficient to promote acylation, for example, about OoOl to about 10 molar equivalents, preferably about OoOl to about 1 equivalent, based on carboxylic acid (III)o The use of such a catalyst leads in many cases to re-markably i~proved yields of maytansinoid compound (I)D

In connection wi-th this reaction, if the carbo~yli~
acid (III) is isomeric, iOeO D- and L-isomers, such isomers may be employed either independently or as an optional mixtureO When compound (I) having an optically active acyl group is desired, the use of the corresponding optical form of carboxylic acid (III) proves advantageous in some instances ~here also are cases in which even the use of an optically active carboxylic acid (III) gives rise to a mixture of D- and L-isomers of maytansinoid compound (I)o The acylation process utilizing a reactive derivative o~ carboxylic acid (III) with respect to its carboxyl function may for example be a process which comprises using a derivative having a func-tional group capable o~
acylating the 3-position of compound (II) such as the acid anhydride (and mixed acid anhydride cyclized through a-OH
and carbonic acid) of carboxylic acid (III). The solvent and catalyst ~or use in this acylation reac-tion may be the same as those mentioned hereinbefore in connection with acylation in -the presence of a carbodiimideO The reaction temperature may usually range from about -20C to about +100C and preferably a~out 20C to about 40Co The reaction may be hastened by heating the reaction system to a s-till higher temperatureO
In the above-mentioned acylation, when a sensitive group (eOgO hydroxyl) which reacts with the acylating agent exists in carboxylic acid (III), said group m~y be protected in advance by a suitable protective group ~eOgO a protecti~Je group in -the form o~ ester: lower alkanoyl (e~g~ form~l, acetyl), hologenated lower alkanoyl (e.g~ trifluoroacetyl, trichloroacetyl, chloroacetyl, bromoacetyl, iodoacetyl) or acyl derived from carbonic acid (eOg~ -tert-butyloxycarbonyl, phenoxycarbonyl); a protective group in the form of ether:
benzyl, di.phenylmethyl, triphenylmethyl or p-me-thoxybenzyl], and after the acylation, the protected compound is subjected to a reaction for removal of the protective group to obtain the contemplated compound (I)o The maytansinoid compound (I) thus produced by the above-mentioned acylation can be isolated by subjecting the reaction mixture to a conventional procedure such as concentration, solvent extraction, chromatography, re-crystalliza-tion, etcO When maytansinoid compound (I) is produced as a mixture o~ isomers (eOgO D- and L-isomers), the isomers can be separated from each other generally by a conventional procedure, eOgO silica gel column chromato-graphyO The maytansinoid compound (I) according to this invention includes such individual isomers and all mixtures o~ the isomersO
The maytansinoid compound (I) according to this invention has strong antimitotic and antitumor activities with comparatively low toxicity and are therefore suited fo~ administration, oral or parenterally, to tumor-bearing warm-blooded animals (eOgO mouse, rat, rabbit, dog, cat and man) for the purpose of prolonging their survival ti~es~
Each compound (I) is normally administered in the form of a pharmaceutical preparation (eDg injectable solution) as formulated wi-th a carrier, diluent or -the like which is kno~n per seO
When cor~pound (I) i5 adminis-tered in the form of an injectable preparation, it may be given subcutaneously, intraperi-toneally, intravenously or intramuscularly, for instanceO The dosage of compound (I) varies with the kind, symptom, administration route, etc~ but, for example, in case of intravenous adminis-tra-tion for prolonging life span of the animal suffering from leukemia or melanoma, it may be decided from the range of about 1 to 1000 ~g/kg body weight, preferably about 10 to 500 ~g/kg body weight, especially about 10 to 200 ~g/kg body weight, per dose~
The injectable preparation can be prepared by the established pharmaceutical procedure; for example by dis-solving about 50 ~g to 3 mg of compound (I) in each about 0~5 ml of alcohol (eOg. ethanol), followed by addition of a sufficient amount of physiological saline to make a total of 10 mlO When a small dosage is indicated, the above solution may be further diluted with physiological saline~
The maytansinoid compounds (I) according to this invention are of value also in that they have antimicrobial activity, eOgO antifungal and antiprotozoal propertiesO
~hus, for example, the maytansinoid compounds (I) are ~s~

useful for tre~ting tetrahymena E~ wO As an antifungal or an-tiprotozoal agen-t1 compound (I) is instrumental in assays of the bacterial flora of soil, active sludge, animal body fluids, etc~ q'hus, for the isolation of useful bacteria from soil samples or in the assay of activity of bacteria to -the exclusion of those of protozoa and fungi in connecti.on with the operation and anal~sis of active sludge systems for waste water treat-ment, the compound (I) can be advantageously employed to ensure selective growth of bacteria without permitting growth of the concomitant protozoa and fungiO ~hus, such a sample is added to a liquid or solid medium, and per milliliter of the inoculated medium, Ool ml of a 1 %
methanol-water solution of about 10 to 100 ~g/ml of compound (I) is added, and then incubated to let the bacteria grow and multiplyO
The maytansinoid compound (I), in an amount of 0002 ml of a 1 mg/ml aqueous solution, is able to inhibit growth of causative microorganisms of stem rot J helminthosporium leaf rot and sheath blight in rice plants, for instance, and can therefore be used for the treatment of such plant diseasesO The procedure may comprise dissolving compound (I) in 1 % aqueous methanol to a concentration of about 005 to 5 ~g/ml and spraying rice plants with the solution.
The following reference example and working examples are in-tended to descri.be this invention in further detail and not -to limit its scopeO

Reference Example ln 800 m~ of dry tetrahydrofuran (TH~?) is dissolved 15~0 g of antibiotic Ansami-tocin mixture (12 % of ansamitocin P-2, 71 % of P-3 and 17 % of P-4) and under dF~ ni-trogen gas streams, the solution is cooled -to -50C in a dry ice-acetone bathO 'rhen, 13~0 g of lithium aluminum hydride (~AH) is added in a single dose and -the mixture is stirred at -50~ to -22C for 2 hoursO ~hen, at -28C, a :further 3 g of L~ is added and -the reaction mixture is s-tirred at -28C to 22C for 80 minu-tesO Thereafter, at -50C, 750 m~ of 2N HC~ is added dropwise with caution and the reaction mixture is extracted three times with 206 ~, 106 e and 008 ,e portions of ethyl acetateO The extracts are pooled, washed with a saturated aqueous solution of sodium chloride (100 me x 2) and d:ried (MgS04, 250 g).
'~he solvent is distilled off under reduced pressure and the residue (1306 g) is chromatographed on a column o:f silica gel (102 kg), elution being carried out with ethyl acetate-water (9805: 105, V/V)0 ~he eluate is collected in 400-gram fractionsO ~ractions 35 through 52 are pooled, the solvent distilled off and the residue dried in vacuo to obtain 7025 g of maytansinolO ~hen~ fractions 53 through 68 are similarly treated to obtain 1055 g of a substantially equimolar mixture of maytansinol and dechloromaytansinolO
Similarly, fractions 69 through 86 yield 0078 g of dechloro-maytansinolO

This product is reprecipitated from chloroform-hexane to obtain 007l g of dechloromaytansinolO
m~pO 174-179C (decompnO ) NMR spectrum (CDC13) ~ ppm: 00~6(3H, s), 1~27(3H, d, J=caO 6Hz)~ 1065(3H, s), 2063(1H, d, J=9Hz), 9007(1H, d, J=13Hz), 3~23(3H, s), 3035(3H, s), 3042(1H, d, J=13T~z), 3075(1H, d, J=9Hz), 3031(3H, s), 4037(1H, m), 5.51(1H, dd, J-9Hz & 15Hz), 6010(1H, d, J=llHz), 6041(1H, dd, J=llHz &
15Hz), 6056(1H, d, J=2Hz), 6060(1H, s), 6070(1H, approxO s), 6097(1H, approx. s), Mass spectrum (m/e): 469, etc~
UV spectrum (~mMeaxH) nm: 23105, 24105, 250.5, 27705, Example 1 In 10 ml of dry dichloromethane are dissolved 56~4 mg of maytansinol, 14408 mg of 0-trifluoroacetyl-DL-mandelic acid, 123~6 mg of dicyclohexylcarbodiimide (DCC) and 2504 mg of 4-dimethylaminopyridine (DMAP), and the solution is stirred at room tempera-tureO After the reaction is completed, 1 ml of a saturated a~ueous solution of sodium hydrogen carbonate i.s added and the mixture is stirred at room temperature for about 30 minutesO l'he organic layer is separated and the water layer extracted twice with 5 ml portions of chloroformO The organic layers are combined and dried~ Then, the solvent is dis-tilled off under reduced -- l L~ --' - .

pressure, and the residue is fractionated and purified by silica gel column chromatographyO By this procedure are obtained two diastereoisomers of maytansinol 3-u-hydro~y-phenylacetate with repsect to the center of asymmetry in the mandelic ester moietyO ~raction I (24 mg, first-emerging fraction); Fraction II (9 mg, later-emerging fraction)O TLC (silica gel; Merck, HPTLC) (solvent: CHC~3-MeOH-95:5): Fraction I, Rf=OoL~4; Fraction II, Rf=0031 Mass spectrum (m/e3: Fraction I, 637 (M+ - 61), 485;
Fraction II, 637 (M~ - 61), 485~

Exarn~le 2 As in Example 1, 200 mg of maytansinol, 306 mg of 2,2-dimethyl-1,3-dioxolan-4-carboxylic acid, 438 mg of DCC
and 90 mg of DMAP are reacted in 15 ml of dry dichloromethane~
The reaction mixture is chromatographed on a column of silica gel using a solvent mixture of chloroform-me-thanol (50 1)o ~his procedure yields two diastereoisomers, with respect to the center of asymmetry in the side chain of maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylateO
Fraction I (111 mg, first-emerging fraction); Fraction II
(30 mg, later-emerging fraction)O T~C (silica gel, Merck, HPT~C): ~raction I, Rf=0053; Fraction II, Rf=0046 (solvent:
chloroform-methanol - 95:5)0 Mass spectrum (m/e); ~raction I, 631 (M+ - 61), 616, 485; Fraction II, 631 (M+ - 61), 6160 ~L3~

Example 3 Of the two diastereoisomers of maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylate o~tainable from maytansinol and 2,2-dimethyl-1,3-dioxolan-4-carboxylate, the fraction having a higher Rf value (Frac-tio~ I) on TLC
(sillca gel, Merck, HPTLC; solvent: chloroform methanol =
95:5) is taken and a 84 mg portion thereof is heated in 2 ml of 70 % a~ueous acetic acid at 60C for about 10 hoursO
The reaction mixture is concentrated to dryness under reduced pressure and the residue is chromatographed on a silica gel column (solvent: acetonitrile-water = 95:5)0 By this procedure is obtained 70 mg of maytansinol 3-(2,3-dihydroxy)propionate (one of diastereoisomers)0 Silica gel TLC (Merck, HPTLC): Rf = 0~50 (solven-t = acetonitrile-water - 95:5); Mass spectrum (m/e): 591 (M+ - 61), 576, By the same procedure as above, 16 mg of the fraction having a lower Rf value (~raction II) was reacted and treated to obtain 8 mg of maytansinol 3-(2,3-dihydroxy) propionate (the other dias-tereoisomer)0 Silica gel ~LC
(Merc~, HPTLC): R~ = 0042 (solvent: acetonitrile-water =
95:5)0 Mass spectrum (m/e): 591 (1~ - 61), 576, 5030 Example 4 In 5 ml of dry dichloromethane are dissolved 108 mg of maytansinol, 257 mg of L-0-acetylmandelic acid and 241 mg of DCC and the mixture is stirred at room temperature for , about 10 ~.inutes. Then, 4807 mg of DMAP is added ar.d stirred at room temperature for an hourO The in.solubles are filtered off, the filtrate concentrated to dryness under reduced pressure and the residue di.ssolved in ethyl acetater The solution is washed with lN-hydrochloric acid, water, saturated aqueous sodium hydrogen carbonate and water in the order men-tionedO The organic layer is taken and dried (over Na2S04) ~nd the solvent is distilled off under reduced pressureO The residue is chromatographed on 75 g silica gel (solvent: ethyl acetate) and the eluate is collected in 15-gram fractionsO Fractions 31 t'nrough 48 are combined and evaporated, whereby 280 5 mg of maytansinol 3-(~-acetoxyphenyl)acetate, which is considered to be one of diastereoisomers with respec-t to the center of asymmetry in ~he si~e c~ , 7 ~ ~tai~d ~ 7 t~ g~7 7 d~
mOp. 177-181C (decompnO) (as recrystallized ~rom ethyl ace-tate-ether) W spectrum ( ~mMaH (nm): 233, 241 (sh), 28105, 28905 Mass ~pectrum (m/e); 679 (M+ - 61) Example 5 In 5 ml of dry dichloromethane are dissolved 100 mg of maytansinol, 221 mg of DL~0-acetyltropic acid and 255 mg of DCC and the mixture is stirred at room temperatureO
After abou-t 5 minu-tes, 64o8 m~ of DI~AP is added and stirred at room temperature overnightO The insolubles are filtered off and the dichloromethane la~er is washed with lN HCR, S~

a satura-t~d aqueous solution of sodium hydrogen carbonate and ~ater in the order mentioned, followed by drying over Na2S04.. Tne solvent is then distilled off, the residue dissolved in ethyl acetate and the insolubles filtered off~
~he filtrate is chromatographed on silica gel (30 g) (solvent = ethyl acetate: water-saturated ethyl acetate =
3:1, v/v) and the eluate is collected in 15-gram fractionsO
~ractions 9 through 13 are combined and evaporated, and the residue rechromatograph.ed on silica gel (30 g) (solvent =
chloroform-methanol = 40:1, v/v), the eluate being collected in 25-gram fractionsO Fractions 5 through 8 are combined and evaporated to give 908 mg of maytansinol 3-~-ace-toxy-methylphenylacetate (one of isomers)O
UV spectrum (~ mMexH (nm)): 232, 24205(sh), 252, 281, 290;
Mass spectrum (m/e): 693 In the first chromatographic run mentioned above, fractions 14 through 21 are combined and evaporated to give 1206 mg of maytansinol 3-~-acetoxymethylphenylacetateO
UV spectrum (~ mMaxH (nm)): 233, 242(sh), 25205, 281, 289;
Mass spectrum (m/e): 693 Exam~le_6 As in Example 1, 130 mg of maytansinol, as a starting ma-terial, 23508 mg of ~-chlorophenylacetic acid, 6102 mg of DMAP and 28409 mg of DCC are reacted in 15 ml of dry ; - 18 -l~L3~jz~jo dichloromethaneO After the reaction has ~een completed, the dicyclohexylurea is filtered off and the filtrate is purified ~y silica gel column chromatography (ethyl acetate:
water-satura-ted ethyl acetate = 9 1)o By this procedure are obtained two diastereoi.somers of may-tansinol 3-~-chlorophenylace-tate with respec-t to the ~-chlorophenyl-acetate moietyO Fraction I (23 mg, first-emerging fraction), Fraction II (~5 mg, later-emergi.ng fraction)0 Silica gel TLC (Merck, HPT~C; developing solvent: chloroform-methanol =
95:5): Fraction I, R~ = 0067; Fraction II, Rf = 00590 Mass spectrum (m/e): ~raction I, 655 (M+ - 61); Fraction II, 655 (M+ - 61)o ~Z
In 5 ml of dichloromethane are dissolved 5304 mg of dechloromaytansinol, 135 mg of 0-acetyl-D-mandelic acid and 129 mg of DCC and the mixture is stirred at room temperature for 5 minutesO Then, 44 mg of DMAP is added and the mixture stirred at room -temperature for an hourO
The insolubles are filtered off, the filtrate concentrated to dryness under reduced pressure and the residue extracted with ethyl acetateO The extract is fractionally purified by silica gel chromatography (silica gel 45 g; solvent =
ethyl acetate: H20-saturated e-Ehyl acetate = 6:1, v/v)0 By the above procedure is obtained 1502 mg of dechloro-maytansinol ~ acetoxyphenylacetate (which is considered to be one of diastereoisomers with respect to the center of asymmetry in -the side chain)0 Sili.ca gel TLC (Merck, HPTLC; solvent: e-thyl aceta-te): ~f = 0029 Mass .spectrum (m/e); 6~5 (M-~ - 61)o Experimen-tal Data Antitumor ac-tivity Therapeutic tests were carried out in mice according to NCl-protocol 1,300, Cancer Chemother, Reports, Part 3, 1972, VolO ~, NoO2, in which melanoma B-16 tumor cells had been intraperitoneally -transplanted, compound (I) being administered intraperitoneally once daily for 9 consecutive daysO Li~e span prolongations obtained are shown in ~able 1 as T/C % valuesO

Table 1 Antitumor Dose ac-tivities Compound (~g/kg) B~16 ~ _ (T/C%) Maytansinol 1205 161 3-~-acetoxyphenylacetate 6025 260 301~5 1~1 Maytansinol 800 217 3-~-hydroxyphenylace-tate 400 247 (Fraction 1) 200 208 ; ~ - 20 -~3S~

Antiprotozoal activity Antiprotozoal activity of compound (I) was assayed with Tetrah,ymena pyriformis W as the tes-t organism and a medium composed of 20 g tryptose-peptone (Difco CoO), l g yeast extract, 2 g glucose, lO00 ml dis-tilled water, lO ml lM phosphate buffer (pH 7O0) as the assay mediurn. The microorga~ism was incubated at 28C for 44 to 48 hours and the growth inhibitory activity of compound (I) was assayed by the serial dilution method. The minimal inhibitory concentrations of compound (I) are shown in Table 2 Table 2 .
Antiprotozoal activity Compound MIC (~g/ml) Tetrahymena pyriformis W

Maytansinol 3-~-acetoxyphenylacetate < 2 Maytansinol 3-~-acetoxyme-thyl-phenylacetate 1 - 2 (from fractions 9-13 of the 1st chromato-graphy) Examples of Pharmaceutical_Composition_ Example A

Composition for Injection (1) Maytansinol 3-a-acetoxyphenylacetate 50 mg (2) ~thanol 10 g ~) Polysorbate 80 (Tween 80) 40 g (4) Mannitol 20 g
(5) Distilled water, a sufficient quantity to make lC00 ml Preparation (1) is dissolved in (2)o To this solution, (3) and (4) are added, followed by the addition of sterilized distilled water to make 1000 ml of the solutionO Ten milliliter each of the solution is used to fill 100 amber ampoules and the air within the ampoules is replaced with nitrogen gas, then the ampoule is sealedO All the processes are conducted under sterile conditionsO

Example B
Composition for Injection (1) Maytansinol 3-a~hydroxyphenylacetate (Frac-tion I) 200 mg --(2) E-thanol 5 g : (3) Polysorbate 80 (Tween 80) 100 g (4) Mannitol 20 g (5) Distilled water, a sufficient quantity to make 1000 ml : Preparation By a similar procedure to that of ~xample A, an injectable solution of (1) is preparedO

Claims (28)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for preparing a compound of the formula:

I

wherein Y is H or C1, and R is C1-15alkyl, phenyl-C1-4alkyl, pyridyl C1-4 alkyl, imidazolyl-C1-4alkyl, indolyl-C1-4alkyl, furyl-C1-4alkyl or thienyl-C1-4alkyl, any of said groups being substituted by hydroxyl, protected hydroxyl, halogen or C1-5alkanoyloxy at its .alpha.-carbon atom or its .beta.-carbon atom or both its .alpha.- and .beta.-carbon atoms, which process comprises acylating maytansinol or dechloromaytansinol of the formula II

II

wherein Y is as defined above, with a carboxylic acid of the formula:

RCOOH III
wherein R is as defined above, or its reactive derivative with respect to the carboxyl function thereof.
2. A process according to claim 1 wherein the group R is substituted on both its .alpha.- and .beta.-carbon atoms by hydroxyl groups which are protected in the form of an acetal.
3. A process according to claim 1 or 2 wherein Y is C1.
4. A process according to claim 1, 2 or 3 wherein R is C2-15 alkyl or phenyl-Cl 4 alkyl, said groups being substituted by hydroxyl, protected hydroxyl, halogen or C1-5 alkanoyloxy at its .alpha.-carbon atom or its .beta.-carbon atom or both its .alpha.- and .beta.-carbon atoms.
5. A process according to claim 1, 2 or 3 wherein the acylation is carried out in the presence of a carbodiimide.
6. A process according to claim 1, 2 or 3 wherein the acylation is carried out in the presence of about 1 to 30 molar equivalents, based on the compound of formula II, of dicyclohexylcarbodiimide.
7. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is .alpha.-hydroxybenzyl.
8. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is (2,2-dimethyl)-1,3-dioxolan-4-yl.
9. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is 1,2-dihydroxy-ethyl.
10. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is .alpha.-acetoxybenzyl.
11. A process acoording to claim 1, 2 or 3 wherein Y is chlorine and R is .alpha.-acetoxyme-thylbenzyl.
12. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is .alpha.-chlorobenzyl.
13. A process according to claim 1, 2 or 3 wherein Y is hydrogen and R is .alpha.-acetoxybenzyl.
14. Compounds of formula I as defined in claim 1 when prepared by a process according to claim 1 or an obvious chemical equivalent thereof.
15. A process for preparing maytansinol 3-.alpha.-hydroxyphenylacetate which comprises reacting maytansinol with 0-trifluoroacetyl-DL-mandelic acid.
16. Maytansinol 3-.alpha.-hydroxyphenylacetate when prepared by a process according to claim 15 or an obvious chemical equivalent thereof.
17. A process for preparing maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylate which comprises reacting maytansinol with 2,2-dimethyl-1,3-dioxolan-4-carboxylic acid.
18. Maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylate when prepared by a process according to claim 17 or an obvious chemical equivalent thereof.
19. A process according to claim 17 which includes the further step of reacting the maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylate with acetic acid to obtain maytansinol 3-(2,3-dihydroxypropionate.
20. Maytansinol 3-(2,3-dihydroxy)propionate when prepared by a process according to claim 19 or an obvious chemical equivalent thereof.
21. A process for preparing maytansinol 3-.alpha.-acetoxyphenylacetate which comprises reacting maytansinol with 0-acetylmandelic acid.
22. Maytansinol 3-.alpha.-acetoxyphenylacetate when prepared by a process according to claim 21 or an obvious chemical equivalent thereof.
23. A process for preparing maytansinol 3-.alpha.-acetoxymethylphenylacetate which comprises reacting maytansinol with O-acetyltropic acid.
24. Maytansinol 3-.alpha.-acetoxymethylphenylacetate when prepared by a process according to claim 23 or an obvious chemical equivalent thereof.
25. A process for preparing maytansinol 3-.alpha.-chlorophenylacetate which comprises reacting maytansinol with .alpha.-chlorophenylacetic acid.
26. Maytansinol 3-.alpha.-chlorophenylacetate when prepared by a process according to claim 25 or an obvious chemical equivalent thereof.
27. A process for preparing dechloromaytansinol 3-.alpha.-acetoxyphenyl-acetate which comprises reacting dechloromaytansinol with O-acetyl mandelic acid.
28. Dechloromaytansinol 3-.alpha.-acetoxyphenylacetate when prepared by a process according to claim 27 or an obvious chemical equivalent thereof.
CA000353518A 1979-06-08 1980-06-06 Maytansinoids, their production and use Expired CA1135260A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP72811/1979 1979-06-08
JP7281179A JPS55164685A (en) 1979-06-08 1979-06-08 Novel maytansinoid compound and its preparation

Publications (1)

Publication Number Publication Date
CA1135260A true CA1135260A (en) 1982-11-09

Family

ID=13500153

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000353518A Expired CA1135260A (en) 1979-06-08 1980-06-06 Maytansinoids, their production and use

Country Status (6)

Country Link
US (1) US4317821A (en)
EP (1) EP0021178B1 (en)
JP (1) JPS55164685A (en)
AT (1) ATE5885T1 (en)
CA (1) CA1135260A (en)
DE (1) DE3066149D1 (en)

Families Citing this family (271)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
AU784157B2 (en) 1999-06-25 2006-02-16 Genentech Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20060270003A1 (en) 2003-07-08 2006-11-30 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
NZ573831A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP1651162B1 (en) 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
AU2004260936B2 (en) 2003-06-27 2010-06-10 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005012531A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
PT2161283E (en) 2003-11-17 2014-08-29 Genentech Inc Compositions comprising antibodies against cd79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
JP2008504007A (en) 2003-12-19 2008-02-14 ジェネンテック・インコーポレーテッド Monovalent antibody fragments useful as therapeutic agents
BRPI0510883B8 (en) * 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
ES2339789T3 (en) 2004-07-20 2010-05-25 Genentech, Inc. PROTEIN 4 INHIBITORS OF ANGIOPOYETINE TYPE, COMBINATIONS AND ITS USE.
ES2532610T3 (en) 2004-07-26 2015-03-30 Genentech, Inc. Procedures and compositions to modulate hepatocyte growth factor activation
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CN104710532B (en) 2004-09-03 2019-01-18 健泰科生物技术公司 The anti-beta 7 antagonists of humanization and its application
DE602006013275D1 (en) 2005-01-07 2010-05-12 Diadexus Inc OVR110 ANTIBODY COMPOSITIONS AND USER METHOD THEREFOR
US7301019B2 (en) * 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
NZ563341A (en) 2005-06-06 2009-10-30 Genentech Inc Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
US8957187B2 (en) * 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
ES2547689T3 (en) 2005-12-02 2015-10-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling that involve antibodies that bind to IL-22 and IL-22R
ES2535856T3 (en) 2005-12-15 2015-05-18 Genentech, Inc. Methods and compositions for targeting polyubiquitin
EP1973950B1 (en) 2006-01-05 2014-09-17 Genentech, Inc. Anti-ephb4 antibodies and methods using the same
KR101617108B1 (en) 2006-01-20 2016-04-29 제넨테크, 인크. Anti-ephrinb2 antibodies and methods using same
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
CA2652945C (en) 2006-05-30 2015-06-02 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
ATE522625T1 (en) 2006-09-12 2011-09-15 Genentech Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER USING PDGFRA, KIT OR KDG GENE AS GENETIC MARKERS
PT2502938E (en) 2006-10-27 2015-06-05 Genentech Inc Antibodies and immunoconjugates and uses therefor
WO2008067283A2 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2008091701A2 (en) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CA2676766A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
WO2008115404A1 (en) * 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CN101802013B (en) 2007-07-16 2014-07-02 健泰科生物技术公司 Humanized anti-CD79b antibodies and immunoconjugates and methods of use
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
WO2010135521A2 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
KR20100097691A (en) 2007-11-12 2010-09-03 테라클론 사이언시스, 아이엔씨. Compositions and methods for the therapy and diagnosis of influenza
TWI580694B (en) 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
MX2010007101A (en) * 2007-12-26 2011-07-01 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells.
ES2475201T3 (en) * 2007-12-26 2014-07-10 Biotest Ag Agents directed against CD138 and their uses
HUE024291T2 (en) * 2007-12-26 2016-01-28 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
JP2011507933A (en) * 2007-12-26 2011-03-10 バイオテスト・アクチエンゲゼルシヤフト Methods for reducing cytotoxic side effects and improving efficacy of immune complexes
WO2009126350A2 (en) 2008-01-18 2009-10-15 Genentech, Inc. Methods and compositions for targeting polyubiquitin
MX2010008437A (en) 2008-01-31 2010-11-25 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use.
MX2010009885A (en) * 2008-03-10 2010-11-30 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of cytomegalovirus infections.
ES2629405T3 (en) 2008-03-18 2017-08-09 Genentech, Inc. Combinations of a drug-antibody anti-HER2 and docetaxel conjugate
EP2279412B1 (en) 2008-04-09 2017-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
CA2723614C (en) * 2008-05-16 2015-07-14 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
PE20120080A1 (en) 2008-10-01 2012-02-17 Genentech Inc ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE
SG172219A1 (en) 2008-12-17 2011-07-28 Genentech Inc Hepatitis c virus combination therapy
SI3260136T1 (en) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv) -neutralizing antibodies
TW201544123A (en) 2009-03-20 2015-12-01 Genentech Inc Anti-HER antibodies
EP2679600A1 (en) * 2009-03-25 2014-01-01 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
RU2598248C2 (en) 2009-04-02 2016-09-20 Роше Гликарт Аг Polyspecific antibodies containing antibody of full length and one-chain fragments fab
CA2759506A1 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
CN102802661B (en) 2009-06-22 2016-01-13 米迪缪尼有限公司 For the engineered Fc district of site-specific conjugation
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
ES2599076T3 (en) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutant and methods of use thereof
SG179196A1 (en) 2009-09-16 2012-04-27 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AR078667A1 (en) 2009-10-19 2011-11-23 Genentech Inc MODULATORS OF ACTIVATOR OF THE HEPATOCIT GROWTH FACTOR (HGFA)
US8435511B2 (en) 2009-10-22 2013-05-07 Genentech, Inc. Anti-hepsin antibodies and methods using same
KR20120105446A (en) 2009-10-22 2012-09-25 제넨테크, 인크. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
KR101968766B1 (en) 2009-11-05 2019-04-12 제넨테크, 인크. Methods and composition for secretion of heterologous polypeptides
AU2010324686B2 (en) 2009-11-30 2016-05-19 Genentech, Inc. Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP2509626B1 (en) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c antibodies and methods using same
CA2784385A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
US8877897B2 (en) 2010-02-23 2014-11-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
CA2796633C (en) 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
BR112012028010A2 (en) 2010-05-03 2017-09-26 Genentech Inc isolated antibody, cell, isolated nucleic acid, method of identifying a first antibody that binds to a tat425 antigenic epitope attached to an antibody, methods of inhibiting cell growth, therapeutic treatment of determining the presence of a tat425 protein and diagnosing the presence of a tumor in a mammal
RU2613886C2 (en) 2010-06-03 2017-03-21 Дженентек, Инк. Antibodies and immunoconjugates rendered by immuno-positron emission tomography, methods of application
EP2603237A4 (en) 2010-08-12 2014-05-21 Theraclone Sciences Inc Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA3201524A1 (en) 2010-08-31 2012-03-08 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
NZ607510A (en) 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
DK2625197T3 (en) 2010-10-05 2016-10-03 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
KR101913448B1 (en) 2011-02-04 2018-10-30 제넨테크, 인크. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2012112489A2 (en) 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
BR112013021863A2 (en) 2011-03-03 2016-11-22 Apexigen Inc il-6 receptor antibodies and methods of use
WO2012125614A1 (en) 2011-03-15 2012-09-20 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
KR20190122889A (en) 2011-04-29 2019-10-30 아펙시젠, 인코포레이티드 Anti-cd40 antibodies and methods of use
MX2013013104A (en) 2011-05-09 2014-10-15 Univ Virginia Patent Found Compositions and methods for treating cancer.
HRP20231066T1 (en) 2011-05-27 2023-10-27 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
KR20140068877A (en) 2011-08-17 2014-06-09 제넨테크, 인크. Inhibition of angiogenesis in refractory tumors
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
EA027900B1 (en) 2011-09-22 2017-09-29 Эмджен Инк. Cd27l antigen binding proteins
AR088509A1 (en) 2011-10-28 2014-06-11 Genentech Inc THERAPEUTIC COMBINATIONS AND METHODS TO TREAT MELANOMA
CA2854153A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
AP2014007638A0 (en) 2011-11-16 2014-05-31 Amgen Inc Methods of treating epidermal growth factor deletion mutant VIII related disorders
CN104302324A (en) 2011-12-08 2015-01-21 生物测试股份公司 Uses of immunoconjugates targeting cd138
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
JP2015509091A (en) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート Humanized antibody
KR20140127854A (en) 2012-02-10 2014-11-04 제넨테크, 인크. Single-chain antibodies and other heteromultimers
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
BR112014027166A2 (en) 2012-05-01 2017-06-27 Genentech Inc antibody, nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, treatment method, proliferation inhibiting method and detection methods.
UY34813A (en) 2012-05-18 2013-11-29 Amgen Inc ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER
CA2871880A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
BR112014028368A2 (en) 2012-06-27 2017-11-14 Hoffmann La Roche method of producing antibody fc region conjugate, antibody fc region conjugate and pharmaceutical formulation
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
NZ739573A (en) 2012-09-26 2019-11-29 Immunogen Inc Improved methods for the acylation of maytansinol
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
ES2728936T3 (en) 2013-01-25 2019-10-29 Amgen Inc Antibodies directed against CDH19 for melanoma
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
MX2015010777A (en) 2013-03-14 2016-04-25 Genentech Inc Anti-b7-h4 antibodies and immunoconjugates.
US9789203B2 (en) 2013-03-15 2017-10-17 Novartis Ag cKIT antibody drug conjugates
PL3004167T3 (en) 2013-05-30 2019-01-31 Kiniksa Pharmaceuticals, Ltd. Oncostatin m receptor antigen binding proteins
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
JP6687520B2 (en) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー Humanized antibody with extremely long complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
EP3738612A1 (en) 2013-07-31 2020-11-18 Biontech AG Diagnosis and therapy of cancer involving cancer stem cells
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
MX2016003256A (en) 2013-09-12 2016-06-07 Halozyme Inc Modified anti-epidermal growth factor receptor antibodies and methods of use thereof.
CN105518027A (en) 2013-09-17 2016-04-20 豪夫迈·罗氏有限公司 Methods of using anti-LGR5 antibodies
JP6502931B2 (en) 2013-10-11 2019-04-17 アメリカ合衆国 TEM 8 antibody and use thereof
EP3066118B1 (en) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
WO2015089344A1 (en) 2013-12-13 2015-06-18 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
CR20160271A (en) 2013-12-16 2016-12-02 Genentech Inc PEPTIDOMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TW201620939A (en) 2014-01-16 2016-06-16 中央研究院 Compositions and methods for treatment and detection of cancers
BR112016015693A2 (en) 2014-01-24 2017-10-24 Genentech Inc Method To Treat Prostate Cancer And Antibody
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
JP6562942B2 (en) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Reactive labeled compounds and uses thereof
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
WO2015171822A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
RU2016150370A (en) 2014-05-22 2018-06-26 Дженентек, Инк. Antibodies and immunoconjugates against GPC3
JP2017518989A (en) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Anti-CD20 glycoengineered antibody group and use thereof
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
WO2015184008A1 (en) 2014-05-27 2015-12-03 Academia Sinica Fucosidase from bacteroides and methods using the same
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TWI732738B (en) 2014-05-28 2021-07-11 中央研究院 Anti-tnf-alpha glycoantibodies and uses thereof
KR20170040249A (en) 2014-08-12 2017-04-12 노파르티스 아게 Anti-cdh6 antibody drug conjugates
JP7286267B2 (en) 2014-08-28 2023-06-05 バイオアトラ インコーポレイテッド Conditionally active chimeric antigen receptor for modified T cells
CA2960712A1 (en) 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
JP7085837B2 (en) 2014-09-12 2022-06-17 ジェネンテック， インコーポレイテッド Anti-HER2 antibody and immune complex
PE20170670A1 (en) 2014-09-12 2017-06-06 Genentech Inc ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES
TW201625689A (en) 2014-09-12 2016-07-16 建南德克公司 Anti-B7-H4 antibodies and immunoconjugates
LT3262071T (en) 2014-09-23 2020-06-25 F. Hoffmann-La Roche Ag Method of using anti-cd79b immunoconjugates
CN106922129B (en) 2014-10-01 2024-02-20 免疫医疗有限责任公司 Methods of conjugating polypeptides
RU2017119185A (en) 2014-11-05 2018-12-05 Дженентек, Инк. ANTIBODIES AGAINST FGFR2 / 3 AND WAYS OF THEIR APPLICATION
PL3227332T3 (en) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Multispecific antibodies
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
AU2016209056B2 (en) 2015-01-24 2021-01-28 Academia Sinica Cancer markers and methods of use thereof
JP6779887B2 (en) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ New glycan conjugate and how to use it
JP2018512597A (en) 2015-02-04 2018-05-17 ジェネンテック， インコーポレイテッド Mutant smoothened and method of using the same
WO2016145536A1 (en) 2015-03-18 2016-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
CN108603170A (en) 2015-06-12 2018-09-28 莱蒂恩技术公司 With the method for engineered T cell treating cancer
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CA3001306A1 (en) 2015-10-09 2017-04-13 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
BR112018015259A2 (en) 2016-01-27 2018-12-18 Medimmune Llc Methods for preparing antibodies with a defined glycosylation standard
CN109195996A (en) 2016-03-08 2019-01-11 中央研究院 The modularity synthetic method of N- glycan and its array
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
SG11201808994YA (en) 2016-04-15 2018-11-29 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
EP3452023A1 (en) 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
ES2930255T3 (en) 2016-05-13 2022-12-09 Bioatla Inc Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
EP3494135A1 (en) 2016-08-02 2019-06-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
JP7160482B2 (en) 2016-09-02 2022-10-25 レンティジェン・テクノロジー・インコーポレイテッド Compositions and methods for treating cancer with DUOCAR
CN110023334B (en) 2016-11-21 2023-11-14 科雅博有限责任公司 anti-GP 73 antibodies and immunoconjugates
WO2018119279A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
JP6706394B1 (en) 2017-01-09 2020-06-03 レンティジェン・テクノロジー・インコーポレイテッドＬｅｎｔｉｇｅｎ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． Compositions and methods for treating cancer by anti-mesothelin immunotherapy
JOP20190187A1 (en) 2017-02-03 2019-08-01 Novartis Ag Anti-ccr7 antibody drug conjugates
AU2018240556A1 (en) 2017-03-24 2019-10-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD33 immunotherapy
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US11389480B2 (en) 2017-05-19 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
AR111963A1 (en) 2017-05-26 2019-09-04 Univ California METHOD AND MOLECULES
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human mesothelin antibodies and uses in cancer therapy
CA3071624A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
ES2960419T3 (en) 2017-09-15 2024-03-04 Lentigen Tech Inc Compositions and methods of cancer treatment with anti-CD19 immunotherapy
WO2019079249A1 (en) 2017-10-16 2019-04-25 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
JP7377802B2 (en) 2017-12-20 2023-11-10 レンティジェン・テクノロジー・インコーポレイテッド Compositions and methods for treating HIV/AIDS using immunotherapy
CA3105694A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
US20210292428A1 (en) 2018-08-08 2021-09-23 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
AU2019343184A1 (en) 2018-09-20 2021-04-15 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
JP2022502043A (en) 2018-09-26 2022-01-11 レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD19 / CD22 Immunotherapy
CN113412119A (en) 2018-11-30 2021-09-17 莱蒂恩技术公司 Compositions and methods for treating cancer with anti-CD 38 immunotherapy
WO2020117257A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
US20220064324A1 (en) 2019-01-08 2022-03-03 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting mesothelin for treating solid tumors
US20220098323A1 (en) 2019-01-22 2022-03-31 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2022524507A (en) 2019-03-06 2022-05-06 レンティジェン・テクノロジー・インコーポレイテッド Compositions and Methods for Treating Cancer with Self-Driven Chimeric Antigen Receptors
WO2020188061A1 (en) 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker
AU2020275415A1 (en) 2019-05-14 2021-11-25 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
CA3140102A1 (en) 2019-05-30 2020-12-03 Dina SCHNEIDER Compositions and methods for treating cancer with anti-bcma immunotherapy
AU2020299382A1 (en) 2019-07-02 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind EGFRvIII and their use
JPWO2021010326A1 (en) 2019-07-12 2021-01-21
TW202122114A (en) 2019-10-18 2021-06-16 美商建南德克公司 Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2021081052A1 (en) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
JP2023506158A (en) 2019-12-12 2023-02-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Antibody-drug conjugates specific for CD276 and uses thereof
WO2021217051A1 (en) 2020-04-24 2021-10-28 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
US11497770B2 (en) 2020-06-22 2022-11-15 Lentigen Technology, Inc. Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
KR20230069211A (en) 2020-09-18 2023-05-18 아라리스 바이오테크 아게 Transglutaminase conjugation method using an amino acid-based linker
WO2022084560A1 (en) 2020-10-25 2022-04-28 Araris Biotech Ag Means and methods for producing antibody-linker conjugates
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CA3171093A1 (en) 2020-11-05 2022-05-12 Dina SCHNEIDER Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022241446A1 (en) 2021-05-12 2022-11-17 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CA3220227A1 (en) 2021-05-28 2022-12-01 Matthew Bruce Combination therapies for treating cancer
WO2022261017A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
WO2023019092A1 (en) 2021-08-07 2023-02-16 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
WO2024026107A2 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
US20240075142A1 (en) 2022-08-26 2024-03-07 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) * 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4137230A (en) * 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) * 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) * 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566586A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation

Also Published As

Publication number Publication date
EP0021178B1 (en) 1984-01-18
DE3066149D1 (en) 1984-02-23
US4317821A (en) 1982-03-02
ATE5885T1 (en) 1984-02-15
JPS55164685A (en) 1980-12-22
EP0021178A1 (en) 1981-01-07

Similar Documents

Publication Publication Date Title
CA1135260A (en) Maytansinoids, their production and use
US4308268A (en) Maytansinoids, pharmaceutical compositions thereof and method of use thereof
CA1133478A (en) Maytansinoids, their production and use
US4256746A (en) Dechloromaytansinoids, their pharmaceutical compositions and method of use
US4309428A (en) Maytansinoids
US4260608A (en) Maytansinoids, pharmaceutical compositions thereof and methods of use thereof
CA2617953C (en) Method of acylating maytansinol with chiral amino acids
US4424219A (en) 9-Thiomaytansinoids and their pharmaceutical compositions and use
CA1135262A (en) Maytansinoids, their production and use
Kupchan et al. Tumor inhibitors. 124. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids
US4190580A (en) Optically active maytansinoids and maytansinoid production method
CA1102798A (en) Production of maytansinoids
KR970011385B1 (en) Disulfur analogs of ll-e33288 antitumor agents
US4264596A (en) Maytansinoids, pharmaceutical compositions thereof and method of use thereof
CA1133901A (en) Dechloromaytansinoids, their production and use
US4263294A (en) Maytansinoids, pharmaceutical compositions thereof and method of use thereof
CA1144096A (en) Demethyl maytansinoids
IE47252B1 (en) Antitumor anthracycline antibiotics
CA1082180A (en) Oxazolidinedione derivatives of vinca alkaloids
KR940009795B1 (en) Process for preparing 2&#39;-substituted-4-deoxythiazolo£5,4-c|rifamycin sv derivatives
USRE30561E (en) Vinca alkaloid intermediates
USRE30560E (en) Oxazolidinedione derivatives of Vinca alkaloids
KR810000812B1 (en) Process for preparing new rifamycin derivatives
JPS6154799B2 (en)

Legal Events

Date Code Title Description
MKEX Expiry